WallStSmart

Merck & Company Inc (MRK)vsPrecision Optics Corporation, Inc. Common stock (POCI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 266164% more annual revenue ($65.01B vs $24.42M). MRK leads profitability with a 28.1% profit margin vs -28.3%. MRK earns a higher WallStSmart Score of 59/100 (C).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

POCI

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued
POCIFair Value (-0.4%)

Margin of Safety

-0.4%

Fair Value

$4.98

Current Price

$4.23

$0.75 premium

UndervaluedFair: $4.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

POCI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
62.8%10/10

Revenue surging 62.8% year-over-year

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

POCI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$45.68M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-73.6%2/10

ROE of -73.6% — below average capital efficiency

Free Cash FlowQuality
$-352,4212/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : POCI

The strongest argument for POCI centers on Revenue Growth. Revenue growth of 62.8% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : POCI

The primary concerns for POCI are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while POCI is a hypergrowth play — different risk/reward profiles.

POCI carries more volatility with a beta of 0.33 — expect wider price swings.

POCI is growing revenue faster at 62.8% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (59/100 vs 32/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Precision Optics Corporation, Inc. Common stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and lighting systems and related components primarily in the United States and the European Economic Area. The company is headquartered in Gardner, Massachusetts.

Want to dig deeper into these stocks?